Today: 9 June 2026
Qantas share price slips again on oil shock — what ASX:QAN investors watch next
3 March 2026
2 mins read

Qantas share price slips again on oil shock — what ASX:QAN investors watch next

Sydney, March 3, 2026, 18:07 AEDT — Market closed.

  • Qantas ended down 1.8% at A$9.24 after touching A$9.04.
  • Oil-linked selling kept airline stocks under pressure as Middle East flight disruptions widened.
  • Next catalysts include Qantas’ March 10 ex-dividend date and a planned March 16 buyback start.

Qantas Airways Limited shares fell again on Tuesday, ending down 1.8% at A$9.24. The stock traded as low as A$9.04 and saw 14.7 million shares change hands, the company’s investor website showed.

The move mattered because travel and airline stocks have been skittish since Monday, when the U.S.-Israel conflict with Iran shut major Gulf hubs and sent oil prices up as much as 13%, lifting the outlook for jet fuel costs. “If the reduction in tanker traffic continues for a week or so it will be historic,” Jim Burkhard, S&P’s global head of crude oil research, said in a Reuters report. Investing.com

Qantas CEO Vanessa Hudson said the airline had “pretty good” fuel hedging, but she called the oil spike a “significant” hit for aviation. Qantas said last week it had 81% of its fuel hedged for the second half of its June 30 financial year, and J.P. Morgan’s Karen Li said investors would “increasingly differentiate” between airlines based on hedging and rerouting as the situation evolves. Reuters

The broader S&P/ASX 200 index fell 1.34% on Tuesday, adding to the pressure on cyclicals such as travel names.

Fuel hedging is meant to smooth swings in jet fuel by locking in prices ahead of time. It can cushion earnings for a while, but it does not remove the risk if oil stays high or if flight disruptions force longer routings that burn more fuel.

The downside case is straightforward: a longer conflict keeps oil elevated, hedges roll off, and demand softens as travellers cancel or delay trips. A sharp move in jet fuel can also pressure ticket pricing and capacity decisions at the wrong point in the cycle.

Investors also have near-term corporate dates on the calendar. An exchange filing shows Qantas declared an interim dividend of 19.8 Australian cents a share, with an ex-dividend date of March 10, a record date of March 11 and payment on April 15. The filing said the dividend is fully franked, meaning it carries Australian tax credits.

In a separate filing, Qantas said it plans an on-market share buyback — purchases on the stock exchange — starting March 16 and running through Dec. 31, targeting up to A$150 million. The company said it could vary the size and retains discretion to buy fewer shares or none.

The ex-dividend date can matter mechanically: from that day, new buyers no longer qualify for the upcoming payout, and shares often adjust lower by roughly the dividend amount. Buybacks can support demand, but only if the company follows through at size.

For the next session, traders will keep one eye on crude and jet fuel pricing and another on any changes to Middle East airspace and flight schedules. On the company side, the March 10 ex-dividend date and the planned March 16 buyback start are the next pinned dates for Qantas shares.

Stock Market Today

  • Regentis Biomaterials Plans European Surgeon Training for GelrinC Implant
    June 9, 2026, 9:53 AM EDT. Regentis Biomaterials' shares edged down to $1.28 ahead of the New York open as the company outlined its European launch strategy for GelrinC, a knee cartilage repair hydrogel implant. The Israeli regenerative-medicine firm will begin surgeon training in Q3 at Humanitas Research Hospital in Milan, marking a key step between CE Mark regulatory clearance and commercial use in Europe. GelrinC's "off-the-shelf" design contrasts with custom-grown products, aiming to ease adoption. However, key uncertainties remain around FDA approval in the U.S., clinical trial outcomes, market acceptance, reimbursement, and competition from established implants by Smith+Nephew and Vericel. Regentis raised $10 million at its December 2025 IPO to fund pivotal U.S. trials and PMA submission. CEO Dr. Ehud Geller called training "critical" for physician adoption ahead of broader rollout.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

Stock Market Today 03.03.2026

Lloyds share price drops again as oil shock hits UK banks ahead of Reeves update
Next Story

Lloyds share price drops again as oil shock hits UK banks ahead of Reeves update

Go toTop